Amie L Fonder
Overview
Explore the profile of Amie L Fonder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
588
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Charalampous C, Claveau J, Kapoor P, Binder M, Buadi F, Cook J, et al.
Blood Adv
. 2025 Jan;
PMID: 39883947
In this study, we first analyzed data from 147 patients with solitary plasmacytomas treated at the Mayo Clinic between 2005 and 2022 and then expanded our investigation through a systematic...
2.
Charalampous C, Goel U, Kapoor P, Binder M, Buadi F, Cook J, et al.
Blood Cancer J
. 2023 Dec;
13(1):183.
PMID: 38072941
No abstract available.
3.
Charalampous C, Goel U, Kapoor P, Binder M, Buadi F, Cook J, et al.
Blood Adv
. 2023 Aug;
7(16):4371-4380.
PMID: 37603349
Patients with multiple myeloma (MM) who do not respond to initial therapy have worse outcomes than primary responders, and effective treatments are lacking in this population. However, the outcomes of...
4.
Charalampous C, Goel U, Kapoor P, Binder M, Buadi F, Dingli D, et al.
Am J Hematol
. 2023 Jan;
98(3):413-420.
PMID: 36588396
Lenalidomide-containing (R) triplet and quadruplet regimens are the standard of care for multiple myeloma (MM) and have been shown to increase the risk of thrombosis. The association between thromboembolism (TE)...
5.
Abdallah N, Binder M, Rajkumar S, Greipp P, Kapoor P, Dispenzieri A, et al.
Blood Cancer J
. 2022 Feb;
12(1):21.
PMID: 35102148
Risk stratification in multiple myeloma is important for prognostication, patient selection for clinical trials, and comparison of treatment approaches. We developed and validated a staging system that incorporates additional FISH...
6.
Abdallah N, Habermann T, Buadi F, Gertz M, Lacy M, Rajkumar S, et al.
Am J Hematol
. 2022 Jan;
97(4):401-410.
PMID: 35015310
Castleman disease (CD) is a rare lymphoproliferative disease characterized by diverse clinical and pathologic features. Due to its rarity, there are limited studies comparing currently available therapies. The role of...
7.
Audil H, Cook J, Greipp P, Kapoor P, Baughn L, Dispenzieri A, et al.
Am J Hematol
. 2021 Oct;
97(1):52-59.
PMID: 34710241
Gain of 1q22 at diagnosis portends poorer outcomes in multiple myeloma (MM), but the prognostic significance of acquired 1q22 gain is unknown. We identified 63 MM patients seen at Mayo...
8.
Muchtar E, Dispenzieri A, Gertz M, Kumar S, Buadi F, Leung N, et al.
Mayo Clin Proc
. 2021 Jun;
96(6):1546-1577.
PMID: 34088417
Immunoglobulin light chain (AL) amyloidosis is a clonal plasma cell disorder leading to progressive and life-threatening organ failure. The heart and the kidneys are the most commonly involved organs, but...
9.
Drosou M, Vaughan L, Muchtar E, Buadi F, Dingli D, Dispenzieri A, et al.
Am J Hematol
. 2021 Jan;
96(4):446-454.
PMID: 33428787
Three sets of criteria (International Society of Amyloidosis [ISA], Palladini and Kastritis) were independently developed for staging, progression and response criteria to predict renal survival in patients with AL amyloidosis....
10.
Hwa Y, Lacy M, Gertz M, Kumar S, Muchtar E, Buadi F, et al.
Eur J Haematol
. 2020 Dec;
106(3):433-436.
PMID: 33259093
No abstract available.